Abstract of the Disclosure

$$R_5(CH_2)_m$$
 R_4
 $R_$

 R_1 is chosen from C_{1-4} alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, H, OR₉, N₃, NR₉R_{9a}, CO₂R₉, SR₉, with the exception wherein R_1 is OH

R₂ is selected from the group of H, halogen, N₃, (CH₂)_mR₅,

 R_3 and R_{3a} are individually chosen from the group consisting of H, OH, halogen, CN, NO₂,

 N_3 , SR_9 , SO_2R_9 , $(CH_2)_mR_5$

 R_4 and R_{4a} are selected from the group of H, OH, Halogen, CN, NO₂, N₃, SR₉, SO₂R₉, (CH₂)_mR₅

X is selected from the group of H, OH, CN, NO2, N3, halogen

Both X and $(CH_2)_mR_5$ together can be =0, =N-OH

 R_5 and R_{5a} are selected from the group of H, OR_9 , NR_9R_{9a} , $C(O)NR_9R_{9a}$, R_9 , R_6 , OR_6 , CO_2R_9 , $C(O)R_9$,

R₆ is chosen from:

R₇ is selected from the group consisting of H, F, SR₈, OR₈

 R_8 is chosen from the group of H, alkyl, alkenyl, alkynyl, aryl, and hydroxyprotecting group, R_9 and R_{9a} are independently selected from the group of H, alkyl, alkenyl, alkynyl, and aryl Y is chosen from CH_2 , CF_2 , CHF, and O,

Z is chosen from O, S,

B is selected from the group of purine, pyrimidine and heterocycle m is 0, 1, 2, 3, or 4 and pharmaceutically acceptable salts thereof and prodrugs thereof.